Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

Sarilumab is a human immunoglobulin G1 anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6 from binding to membrane-bound and soluble IL-6 receptor α. This bridging study assessed the effic...

Source: Arthritis Research and Therapy - March 20, 2019 Category: Rheumatology Authors: Yoshiya Tanaka, Kazuteru Wada, Yoshinori Takahashi, Owen Hagino, Hubert van Hoogstraten, Neil M. H. Graham and Hideto Kameda Tags: Research Source Type: research